<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="bcp16362" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">BCP</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11999052</article-id><article-id pub-id-type="pmcid-ver">PMC11999052.1</article-id><article-id pub-id-type="pmcaid">11999052</article-id><article-id pub-id-type="pmcaiid">11999052</article-id><article-id pub-id-type="pmid">39648680</article-id><article-id pub-id-type="doi">10.1111/bcp.16362</article-id><article-id pub-id-type="publisher-id">BCP16362</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Systematic review and meta&#8208;analysis of vancomycin therapeutic level for treatment of vancomycin&#8208;sensitive enterococcal infections</article-title><alt-title alt-title-type="left-running-head">Katip et al.</alt-title></title-group><contrib-group><contrib id="bcp16362-cr-0001" contrib-type="author"><name name-style="western"><surname>Katip</surname><given-names initials="W">Wasan</given-names></name><xref rid="bcp16362-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bcp16362-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bcp16362-cr-0002" contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="SWH">Shaun Wen Huey</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7361-6576</contrib-id><xref rid="bcp16362-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="bcp16362-cr-0003" contrib-type="author"><name name-style="western"><surname>Kasatpibal</surname><given-names initials="N">Nongyao</given-names></name><xref rid="bcp16362-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="bcp16362-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="bcp16362-cr-0004" contrib-type="author" corresp="yes"><name name-style="western"><surname>Rayanakorn</surname><given-names initials="A">Ajaree</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5961-8978</contrib-id><xref rid="bcp16362-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="bcp16362-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>ajaree.rayanakorn@cmu.ac.th</email><email>au.ajaree@gmail.com</email></address></contrib></contrib-group><aff id="bcp16362-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmaceutical Care, Faculty of Pharmacy</named-content>
<institution>Chiang Mai University</institution>
<city>Chiang Mai</city>
<country country="TH">Thailand</country>
</aff><aff id="bcp16362-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Epidemiological and Innovative Research Group for Infectious Diseases (EIRGID)</named-content>
<institution>Chiang Mai University</institution>
<city>Chiang Mai</city>
<country country="TH">Thailand</country>
</aff><aff id="bcp16362-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">School of Pharmacy</named-content>
<institution>Monash University Malaysia, Jalan Lagoon Selatan</institution>
<city>Bandar Sunway</city>
<named-content content-type="country-part">Selangor</named-content>
<country country="MY">Malaysia</country>
</aff><aff id="bcp16362-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Division of Nursing Science, Faculty of Nursing</named-content>
<institution>Chiang Mai University</institution>
<city>Chiang Mai</city>
<country country="TH">Thailand</country>
</aff><aff id="bcp16362-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacology, Faculty of Medicine</named-content>
<institution>Chiang Mai University</institution>
<city>Chiang Mai</city>
<country country="TH">Thailand</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Ajaree Rayanakorn, Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.<break/>
Email: <email>ajaree.rayanakorn@cmu.ac.th</email>; <email>au.ajaree@gmail.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>91</volume><issue seq="330">4</issue><issue-id pub-id-type="pmc-issue-id">486505</issue-id><issue-id pub-id-type="doi">10.1002/bcp.v91.4</issue-id><issue-title>Themed Issue: What can pharmacokinetic modelling do for you? Rational design and interpretation of clinical studies</issue-title><fpage>1250</fpage><lpage>1262</lpage><history><date date-type="rev-recd"><day>05</day><month>11</month><year>2024</year></date><date date-type="received"><day>18</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>15</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-16 11:25:53.057"><day>16</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">British Journal of Clinical Pharmacology</italic> published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BCP-91-1250.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:BCP-91-1250.pdf"/><abstract><title>Abstract</title><sec id="bcp16362-sec-0001"><title>Aims</title><p>Evidence on the optimal targets of vancomycin for treating other Gram&#8208;positive infections apart from methicillin&#8208;resistant <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Staphylococcus aureus</italic>
</styled-content> (MRSA) is lacking. This review aims to identify the recommended vancomycin therapeutic level for favourable clinical outcomes among patients infected with vancomycin&#8208;sensitive enterococcal infections.</p></sec><sec id="bcp16362-sec-0002"><title>Methods</title><p>Analytical studies describing the vancomycin levels of vancomycin&#8208;sensitive enterococcal infections among adult population were searched. The primary outcome was 30&#8208;day all&#8208;cause mortality, and the secondary outcomes were clinical failure and nephrotoxicity. Study characteristics were extracted and pooled using random&#8208;effects meta&#8208;analysis. The study quality was assessed using the Joanna Briggs Institute critical appraisal tool.</p></sec><sec id="bcp16362-sec-0003"><title>Results</title><p>A total of nine retrospective cohorts studies involving 1013 patients with vancomycin&#8208;sensitive enterococci were included. The meta&#8208;analysis found that high area under the curve to minimum inhibitory concentration ratio (AUC/MIC) of vancomycin &#8805; 389&#8201;mg*h/L significantly lowered the 30&#8208;day mortality (odds ratio [OR], 0.44, 95% confidence interval [CI], 0.26&#8211;0.75). Analysis of the target AUC/MIC showed that high vancomycin AUC/MIC (&#8805; 389&#8211;400&#8201;mg*h/L) significantly reduced clinical failure rate (OR 0.59, 95% CI 0.37&#8211;0.94). The mortality and treatment failure rates did not differ significantly between those with high or low trough levels. Higher vancomycin AUC/MIC and trough levels were significantly associated with increased nephrotoxicity (OR 3.11, 95% CI 1.65&#8211;5.89; OR 2.95, 95% CI 1.60&#8211;5.44, respectively).</p></sec><sec id="bcp16362-sec-0004"><title>Conclusions</title><p>The use of a higher vancomycin AUC/MIC concentration can be effective to reduce 30&#8208;day mortality and clinical failure but this needs to take into consideration the risk of nephrotoxicity. Well&#8208;conducted prospective studies are warranted due to the scarcity of evidence.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bcp16362-kwd-0001">AUC</kwd><kwd id="bcp16362-kwd-0002">enterococci</kwd><kwd id="bcp16362-kwd-0003">pharmacokinetic</kwd><kwd id="bcp16362-kwd-0004">therapeutic level</kwd><kwd id="bcp16362-kwd-0005">trough</kwd><kwd id="bcp16362-kwd-0006">vancomycin</kwd></kwd-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="13"/><word-count count="7000"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:12.04.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bcp16362-cit-9001"><string-name name-style="western"><surname>Katip</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SWH</given-names></string-name>, <string-name name-style="western"><surname>Kasatpibal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Rayanakorn</surname><given-names>A</given-names></string-name>. <article-title>Systematic review and meta&#8208;analysis of vancomycin therapeutic level for treatment of vancomycin&#8208;sensitive enterococcal infections</article-title>. <source>Br J Clin Pharmacol</source>. <year>2025</year>;<volume>91</volume>(<issue>4</issue>):<fpage>1250</fpage>&#8208;<lpage>1262</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcp.16362</pub-id><pub-id pub-id-type="pmid">39648680</pub-id><pub-id pub-id-type="pmcid">PMC11999052</pub-id></mixed-citation>
</p></notes></front><body id="bcp16362-body-0001"><boxed-text position="float" content-type="box" id="bcp16362-blk-0001" orientation="portrait"><sec id="bcp16362-sec-0006"><title>What is already known about this subject</title><p>
<list list-type="bullet" id="bcp16362-list-0001"><list-item id="bcp16362-li-0001"><p>
<italic toggle="yes">Enterococci</italic> are facultative anaerobic Gram&#8208;positive cocci that result in serious hospital&#8208;acquired infections, and can be effectively treated with vancomycin, a glycopeptide antibiotic.</p></list-item><list-item id="bcp16362-li-0002"><p>Vancomycin therapeutic drug monitoring (TDM) is recommended due to its risk of nephrotoxicity.</p></list-item><list-item id="bcp16362-li-0003"><p>Evidence on the optimal targets of vancomycin for treating methicillin&#8208;resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) has been established. However, the target vancomycin concentrations for treating enterococcal infections remains controversial.</p></list-item></list>
</p></sec><sec id="bcp16362-sec-0007"><title>What this study adds</title><p>
<list list-type="bullet" id="bcp16362-list-0002"><list-item id="bcp16362-li-0004"><p>High vancomycin AUC/MIC &#8805; 389&#8201;mg*h/L and &#8805; 389&#8211;400&#8201;mg*h/L was significantly associated with reduced 30&#8208;day mortality and lowered treatment failure rates among patients infected with enterococcal infections.</p></list-item><list-item id="bcp16362-li-0005"><p>High vancomycin trough regimen may not be superior to low trough regimen in terms of clinical effects in treating enterococcal infections.</p></list-item><list-item id="bcp16362-li-0006"><p>Both high vancomycin AUC/MIC and trough concentrations were associated with higher nephrotoxicity rate.</p></list-item></list>
</p></sec></boxed-text><sec id="bcp16362-sec-0008"><label>1</label><title>INTRODUCTION</title><p>
<italic toggle="yes">Enterococci</italic> are short&#8208; and medium&#8208;chain Gram&#8208;positive anaerobic cocci bacteria which pose significant challenges in healthcare settings globally.<xref rid="bcp16362-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="bcp16362-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> These include <italic toggle="yes">Enterococcus faecalis</italic> and <italic toggle="yes">Enterococcus faecium</italic> which are common causes of hospital&#8208;acquired infections (HAIs), particularly in the urinary tract and bloodstream, and in some cases cause serious infections resulting in infective endocarditis, bacteraemia, peritonitis and even death.<xref rid="bcp16362-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Due to the bacteria's survival ability in the environment and resistance to many anti&#8208;bactericidal agents, enterococcal infection is usually difficult to treat.<xref rid="bcp16362-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</p><p>Vancomycin is a glycopeptide antibiotic that has a broad spectrum of activity against Gram&#8208;positive bacteria such as methicillin&#8208;resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) and <italic toggle="yes">Enterococci</italic>. It is also useful for patients with beta&#8208;lactam&#8208;resistant enterococcal infection and individuals who are contraindicated to beta&#8208;lactam antibiotics due to adverse drug reactions.<xref rid="bcp16362-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> However, due to its major adverse events such as nephrotoxicity, therapeutic drug monitoring (TDM) of vancomycin is required to reduce the risk of toxicity while maximizing therapeutic efficacy. Clinical evidence suggests that the use of vancomycin at the area under the curve to minimum inhibitory concentration ratio (AUC/MIC) of &#8805; 389&#8201;mg*h/L is associated with better outcomes including reduced mortality rates,<xref rid="bcp16362-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> but the higher vancomycin serum concentrations may potentially result in nephrotoxicity. To overcome this, vancomycin trough&#8208;guided dosage has been suggested as a more practical option due to less need for serum collections.<xref rid="bcp16362-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="bcp16362-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="bcp16362-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> However, recent studies have found that a high trough concentration was associated with nephrotoxicity and these levels were poorly correlated with the AUC<sub>24</sub>/MIC level.<xref rid="bcp16362-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="bcp16362-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Currently, the optimal vancomycin concentrations targeting a trough level of 15&#8211;20&#8201;mg/L to achieve AUC/MIC level &#8805; 400&#8201;mg*h/L for methicillin&#8208;resistant <italic toggle="yes">S. aureus</italic> (MRSA) infection have been recommended.<xref rid="bcp16362-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="bcp16362-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> However, there is a paucity of evidence concerning the optimal vancomycin concentration in the management of Gram&#8208;positive infections in addition to MRSA, particularly <italic toggle="yes">Enterococcus</italic> spp. This systematic review and meta&#8208;analysis was conducted in order to identify appropriate vancomycin therapeutic level for optimal clinical outcomes including 30&#8208;day mortality, clinical failure and nephrotoxicity among patients infected with vancomycin&#8208;sensitive enterococcal infections.</p></sec><sec sec-type="methods" id="bcp16362-sec-0009"><label>2</label><title>METHODS</title><p>This systematic review and meta&#8208;analysis was carried out according to the study protocol registered on PROSPERO (CRD42022380008). The study was reported following the Preferred Reporting Items for Systematic Reviews and Meta&#8208;analyses (PRISMA) statement.<xref rid="bcp16362-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="bcp16362-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The Research Ethics Committee of the Faculty of Medicine, Chiang Mai University, granted an exemption for this study protocol (Study No. PHA&#8208;2567&#8208;0618).</p><sec id="bcp16362-sec-0010"><label>2.1</label><title>Search strategy and study selection</title><p>A systematic search was performed in EMBASE, PubMed, Web of Science and Scopus using Medical Subject Headings (MeSH) terms &#8220;(Vancomycin) AND (enteroccoci) AND (AUC* OR trough*)&#8221; in humans without time or language restriction up to 19 March 2024 (Supplementary material, Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">1</xref>). Articles were included if they were analytical studies (case controls, cohort studies, experimental/randomized controlled trials [RCTs]) with TDM of vancomycin therapeutic level in vancomycin&#8208;sensitive enterococcal infections among adult patients. We excluded qualitative studies, case series, case reports, review, systematic review and meta&#8208;analysis studies. The references cited in the identified articles were also cross&#8208;checked to identify potential additional articles.</p></sec><sec id="bcp16362-sec-0011"><label>2.2</label><title>Primary and secondary outcomes</title><p>The primary outcome of interest was 30&#8208;day all&#8208;cause mortality, which was defined as fatality from any cause during 30&#8201;days following enterococcal infection. Secondary outcomes were clinical failure, defined as partial or no improvement of leucocytosis, fever and local signs and symptoms of enterococcal infections after completing the treatment. Adverse event nephrotoxicity was defined by the 2009 vancomycin consensus guideline as an increase in serum creatinine (SCr) of 0.5&#160;mg/dL or 50% higher than the baseline of two consecutive measurement occasions<xref rid="bcp16362-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> or the more sensitive Risk, Injury, Failure, Loss, and End&#8208;stage Kidney (RIFLE) criteria<xref rid="bcp16362-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> or the Kidney Disease Improving Global Outcomes (KDIGO) criteria.<xref rid="bcp16362-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</p></sec><sec id="bcp16362-sec-0012"><label>2.3</label><title>Data extraction</title><p>Studies were screened and identified for inclusion by A.R. and checked against the inclusion criteria by W.K. Eligible studies were extracted by A.R. and W.K., and data were confirmed by S.W.H.L. and N.K. Discrepancies or disagreements were resolved through discussions until consensus was reached.</p></sec><sec id="bcp16362-sec-0013"><label>2.4</label><title>Risk of bias assessment</title><p>The Joanna Briggs Institute (JBI)&#8217;s critical appraisal tool was applied according to the relevant study design of the included studies.<xref rid="bcp16362-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Three reviewers (A.R., W.K., S.W.H.L.) independently assessed the risk of bias of studies included based on the critical appraisal checklist for cohort studies by the JBI.<xref rid="bcp16362-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> The checklist contains 11 questions in which the answer could be &#8220;yes&#8221;, &#8220;no&#8221;, &#8220;not applicable&#8221; or &#8220;unclear&#8221; to evaluate specific domains in terms of the potential risk of bias of each included study. Any controversy or discrepancies were resolved through consultation with all authors to reach a consensus. Each study's risk of bias was categorized into low risk of bias when more than 70% of &#8220;yes&#8221; scores was reached, moderate risk of bias if the study's scores of &#8220;yes&#8221; ranged from 50% to 69% and high risk of bias when the study's &#8220;yes&#8221; scores reached up to 49%.<xref rid="bcp16362-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</p></sec><sec id="bcp16362-sec-0014"><label>2.5</label><title>Data analysis</title><p>A random effects meta&#8208;analyses for the odds ratios (ORs) were used to assess the association between the vancomycin low and high trough level (&lt; 15&#8201;mg/L <italic toggle="yes">vs</italic>. &#8805; 15&#8201;mg/L) or AUC<sub>24</sub>/MIC ratio &lt; 389&#8201;mg*h/L <italic toggle="yes">vs</italic>. &#8805; 389&#8201;mg*h/L. The effect sizes (ES) for each study were displayed using forest plots with corresponding 95% confidence intervals (CIs) and overall estimated ES, and the <italic toggle="yes">I</italic>
<sup>2</sup> statistic was used to test for levels of heterogeneity. Sources of heterogeneity, according to study&#8208;specific characteristics (e.g., population, clinical/outcome measurement) were also explored. STATA version 16.1 (College Station, TX, USA) was used for all analyses.</p></sec></sec><sec sec-type="results" id="bcp16362-sec-0015"><label>3</label><title>RESULTS</title><sec id="bcp16362-sec-0016"><label>3.1</label><title>Study selection</title><p>Of the 4853 records identified, 4795 articles remained after removing duplicates. Upon title and abstract screening, 4760 irrelevant studies were excluded, with 35 studies undergoing full text eligibility assessment. An additional five articles were also identified from other sources (two studies from websites, and three studies from verification of the reference lists) which underwent eligibility assessment. Of these, nine studies met the inclusion/exclusion criteria and were included in the review (Figure&#160;<xref rid="bcp16362-fig-0001" ref-type="fig">1</xref>) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S1.1</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">1</xref>). Details of the 27 studies excluded after being reviewed in full are presented in Table&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S1.1</xref> in the Supporting Information.</p><fig position="float" fig-type="FIGURE" id="bcp16362-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Flow diagram of search strategy and study selection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="BCP-91-1250-g002.jpg"/></fig></sec><sec id="bcp16362-sec-0017"><label>3.2</label><title>Study characteristics</title><p>All included studies were retrospective cohort studies, which included 1013 patients with a mean age of 60&#8211;74&#8201;years who had enterococcal infections treated with vancomycin. Patients who had polymicrobial bacteraemia, unmeasured serum vancomycin, renal replacement therapy and isolates resistant to vancomycin were excluded. Sample size among studies ranged between 37 and 312 single or first episode of infection. Four studies were performed in Japan,<xref rid="bcp16362-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="bcp16362-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="bcp16362-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="bcp16362-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> two studies each in Thailand<xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> and South Korea<xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="bcp16362-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> and one study in Singapore.<xref rid="bcp16362-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> The included studies' characteristics are summarized in Table&#160;<xref rid="bcp16362-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="bcp16362-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Summary of study characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">No</th><th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">First author Year</th><th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Country</th><th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Study design</th><th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Population</th><th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">
<italic toggle="no">N</italic>
</th><th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Mean age</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">30&#8208;day all&#8208;cause mortality</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">30&#8208;day all&#8208;cause mortality</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Nephrotoxicity</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Nephrotoxicity</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Clinical failure</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Clinical failure</th><th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Target AUC/MIC break point (mg*h/L)</th><th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Target trough break point (mg/L)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Low trough <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">High trough <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Low AUC/MIC <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">High AUC/MIC <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Low trough <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">High trough <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Low AUC/MIC <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">High AUC/MIC <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Low trough <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">High Trough <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Low AUC/MIC <italic toggle="no">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">High AUC/MIC <italic toggle="no">n</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Jumah et al.</p>
<p>2018</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Singapore</td><td align="left" valign="top" rowspan="1" colspan="1">R, Co</td><td align="left" valign="top" rowspan="1" colspan="1">Patients with enterococcus bacteraemia</td><td align="left" valign="top" rowspan="1" colspan="1">57</td><td align="left" valign="top" rowspan="1" colspan="1">73.6<xref rid="bcp16362-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">5/11 (45.5)</td><td align="left" valign="top" rowspan="1" colspan="1">5/46 (10.9)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">1/11 (9.1)</td><td align="left" valign="top" rowspan="1" colspan="1">3/46 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 389.08</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Nakakura et al. 2019</td><td align="left" valign="top" rowspan="1" colspan="1">Japan</td><td align="left" valign="top" rowspan="1" colspan="1">R, Co</td><td align="left" valign="top" rowspan="1" colspan="1">Patients with <italic toggle="yes">Enterococcus faecium</italic> bacteraemia</td><td align="left" valign="top" rowspan="1" colspan="1">45</td><td align="left" valign="top" rowspan="1" colspan="1">73.0</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">3/8 (37.5)</td><td align="left" valign="top" rowspan="1" colspan="1">9/37 (24.3)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">1/8 (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">10/37 (27.0)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 389</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">Sohn et al. 2021</td><td align="left" valign="top" rowspan="1" colspan="1">South Korea</td><td align="left" valign="top" rowspan="1" colspan="1">R, Co</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Patients with <italic toggle="yes">E. faecium</italic>, <italic toggle="yes">Enterococcus faecalis</italic>
</p>
<p>bacteraemia</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">37</td><td align="left" valign="top" rowspan="1" colspan="1">60.4</td><td align="left" valign="top" rowspan="1" colspan="1">7/19<xref rid="bcp16362-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref> (36.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1/18<xref rid="bcp16362-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref> (5.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2/7<xref rid="bcp16362-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref> (28.6)</td><td align="left" valign="top" rowspan="1" colspan="1">6/30<xref rid="bcp16362-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref> (20.0)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 389</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">Katip &amp; Oberdorfer 2021</td><td align="left" valign="top" rowspan="1" colspan="1">Thailand</td><td align="left" valign="top" rowspan="1" colspan="1">R, Co</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Patients with <italic toggle="yes">E. faecium</italic>, <italic toggle="yes">E. faecalis</italic>
</p>
<p>bacteraemia</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">312</td><td align="left" valign="top" rowspan="1" colspan="1">61.2</td><td align="left" valign="top" rowspan="1" colspan="1">16/87 (15.5)</td><td align="left" valign="top" rowspan="1" colspan="1">31/178 (14.8)</td><td align="left" valign="top" rowspan="1" colspan="1">13/65 (16.7)</td><td align="left" valign="top" rowspan="1" colspan="1">14/200 (14.5)</td><td align="left" valign="top" rowspan="1" colspan="1">15/88 (14.6)</td><td align="left" valign="top" rowspan="1" colspan="1">58/151 (27.8)</td><td align="left" valign="top" rowspan="1" colspan="1">3/78 (3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">35/234 (15.0)</td><td align="left" valign="top" rowspan="1" colspan="1">21/82 (20.4)</td><td align="left" valign="top" rowspan="1" colspan="1">33/176 (15.8)</td><td align="left" valign="top" rowspan="1" colspan="1">17/78 (21.8)</td><td align="left" valign="top" rowspan="1" colspan="1">37/234 (15.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 400</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Nham et al.</p>
<p>2022</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">South Korea</td><td align="left" valign="top" rowspan="1" colspan="1">R, Co</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Patients with <italic toggle="yes">E. faecium</italic>,</p>
<p>enterococcus <italic toggle="yes">b</italic>acteraemia</p>
<p>
<underline underline-style="single">
<italic toggle="yes">Note:</italic>
</underline> 87.7% of patients had solid or hematologic malignancies</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">65</td><td align="left" valign="top" rowspan="1" colspan="1">60.0</td><td align="left" valign="top" rowspan="1" colspan="1">1/37 (2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">8/28 (28.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0/22 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">9/43 (20.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3/37 (8.1)</td><td align="left" valign="top" rowspan="1" colspan="1">11/28 (39.3)</td><td align="left" valign="top" rowspan="1" colspan="1">2/22 (9.1)</td><td align="left" valign="top" rowspan="1" colspan="1">12/4 (27.9)</td><td align="left" valign="top" rowspan="1" colspan="1">7/37 (19.4)</td><td align="left" valign="top" rowspan="1" colspan="1">8/28 (28.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3/22 (13.6)</td><td align="left" valign="top" rowspan="1" colspan="1">12/43 (27.9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 504</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 13.94</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">Katip et al. 2022</td><td align="left" valign="top" rowspan="1" colspan="1">Thailand</td><td align="left" valign="top" rowspan="1" colspan="1">R, Co</td><td align="left" valign="top" rowspan="1" colspan="1">Patients with <italic toggle="yes">E. faecium (73%), E. faecalis (27%)</italic> bacteraemia</td><td align="left" valign="top" rowspan="1" colspan="1">300</td><td align="left" valign="top" rowspan="1" colspan="1">60.9</td><td align="left" valign="top" rowspan="1" colspan="1">16/83 (19.3)</td><td align="left" valign="top" rowspan="1" colspan="1">21/166 (12.7)</td><td align="left" valign="top" rowspan="1" colspan="1">12/60 (20.0)</td><td align="left" valign="top" rowspan="1" colspan="1">25/189 (13.23)</td><td align="left" valign="top" rowspan="1" colspan="1">7/83 (8.4)</td><td align="left" valign="top" rowspan="1" colspan="1">43/166 (25.9)</td><td align="left" valign="top" rowspan="1" colspan="1">6/60 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">44/189 (23.3)</td><td align="left" valign="top" rowspan="1" colspan="1">19/83 (22.9)</td><td align="left" valign="top" rowspan="1" colspan="1">23/166 (13.9)</td><td align="left" valign="top" rowspan="1" colspan="1">13/60 (21.7)</td><td align="left" valign="top" rowspan="1" colspan="1">29/189 (15.3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 389</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7.</td><td align="left" valign="top" rowspan="1" colspan="1">Komatsu et al. 2023</td><td align="left" valign="top" rowspan="1" colspan="1">Japan</td><td align="left" valign="top" rowspan="1" colspan="1">R, Co</td><td align="left" valign="top" rowspan="1" colspan="1">Patients with <italic toggle="yes">E. faecium</italic> bacteraemia</td><td align="left" valign="top" rowspan="1" colspan="1">87</td><td align="left" valign="top" rowspan="1" colspan="1">69.6<xref rid="bcp16362-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">6/9 (66.7)</td><td align="left" valign="top" rowspan="1" colspan="1">8/78 (10.3)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 414.3</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8.</td><td align="left" valign="top" rowspan="1" colspan="1">Sasano &amp; Hanada 2023</td><td align="left" valign="top" rowspan="1" colspan="1">Japan</td><td align="left" valign="top" rowspan="1" colspan="1">R, Co</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Patients with <italic toggle="yes">E. faecium</italic> bacteraemia</p>
<p>
<underline underline-style="single">
<italic toggle="yes">Note:</italic>
</underline> 63.4% of patients had a malignant tumour</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">41</td><td align="left" valign="top" rowspan="1" colspan="1">68.6<xref rid="bcp16362-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">5/32 (15.6)</td><td align="left" valign="top" rowspan="1" colspan="1">4/9 (44.4)</td><td align="left" valign="top" rowspan="1" colspan="1">2/8 (25)</td><td align="left" valign="top" rowspan="1" colspan="1">7/33 (21.2)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 389</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9.</td><td align="left" valign="top" rowspan="1" colspan="1">Tochikura et al. 2023</td><td align="left" valign="top" rowspan="1" colspan="1">Japan</td><td align="left" valign="top" rowspan="1" colspan="1">R, Co</td><td align="left" valign="top" rowspan="1" colspan="1">Patients with <italic toggle="yes">E. faecium</italic> bacteraemia</td><td align="left" valign="top" rowspan="1" colspan="1">69</td><td align="left" valign="top" rowspan="1" colspan="1">74</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">2/13 (15.4)</td><td align="left" valign="top" rowspan="1" colspan="1">3/56 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1/8 <sup>c</sup> (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">6/61<xref rid="bcp16362-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref> (9.8)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">5/32 (15.6)</td><td align="left" valign="top" rowspan="1" colspan="1">7/37 (18.9)</td><td align="left" valign="top" rowspan="1" colspan="1">5/13 (38.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7/56 (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8805; 389</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>&#8805; 15,</p>
<p>&#8805; 20<xref rid="bcp16362-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</p>
</td></tr></tbody></table><table-wrap-foot id="bcp16362-ntgp-0001"><fn id="bcp16362-note-0001"><p>
<italic toggle="yes">Note</italic>:</p></fn><fn id="bcp16362-note-0002"><label>
<sup>a</sup>
</label><p>Estimated mean based on calculation from Luo et al. 2018<xref rid="bcp16362-note-0005" ref-type="table-fn">
<sup>1</sup>
</xref>;</p></fn><fn id="bcp16362-note-0003"><label>
<sup>b</sup>
</label><p>28&#8208;day all&#8208;cause mortality;</p></fn><fn id="bcp16362-note-0004"><label>
<sup>c</sup>
</label><p>Target trough breakpoint &#8805; 20&#8201;mg/L was used for nephrotoxicity; AUC, area under the concentration&#8211;time curve; C, cohort study; MIC, minimum inhibitory concentration; NA, not applicable; R, retrospective.</p></fn><fn id="bcp16362-note-0005"><label>
<sup>1</sup>
</label><p>Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid&#8208;range, and/or mid&#8208;quartile range. Stat Methods Med Res. 2018;27(6):1785&#8211;805.</p></fn></table-wrap-foot></table-wrap><p>All included studies assessed 30&#8208;day all&#8208;cause mortality except Sohn et al. whose primary outcome was 28&#8208;day all&#8208;cause mortality.<xref rid="bcp16362-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The target AUC/MIC breakpoint of &#8805;389&#8201;mg*h/L was used in six studies<xref rid="bcp16362-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="bcp16362-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="bcp16362-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="bcp16362-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="bcp16362-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> while two studies targeted the AUC/MIC ratio of 400&#8201;mg*h/L<xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> and 414.3&#8201;mg*h/L,<xref rid="bcp16362-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> respectively. Another study employed a target AUC/MIC breakpoint of &#8805;504&#8201;mg*h/L.<xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> The therapeutic target of vancomycin trough level of 15&#8201;mg/L was used in all studies except in Nham et al., in which the target trough concentration of 13.94&#8201;mg/L during the first 72&#8201;h was applied.<xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Tochikura et al. targeted a trough breakpoint of 20&#8201;mg/L to investigate the association between vancomycin pharmacokinetics and nephrotoxicity.<xref rid="bcp16362-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><p>Different methods were used for minimum inhibitory concentration (MIC) determination. Four studies<xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="bcp16362-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> used the VITEK&#8208;2 system, of which one study also confirmed vancomycin MICs by the broth microdilution (BMD).<xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> One study performed gradient diffusion E test compared with BMD and found 100% categorical agreement,<xref rid="bcp16362-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> while four studies employed an automated microdilution method.<xref rid="bcp16362-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="bcp16362-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="bcp16362-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="bcp16362-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> All studies reported using the Clinical and Laboratory Standards Institute (CLSI) guidelines (MIC of &#8805; 32&#160;&#956;g/mL for vancomycin).</p></sec><sec id="bcp16362-sec-0018"><label>3.3</label><title>Meta&#8208;analysis</title><p>A total of 1013 patients with enterococcal infections receiving vancomycin treatment in nine studies were included in the analyses. Meta&#8208;analysis for the odds ratios (ORs) comparing individuals with the high and low concentration of vancomycin trough &#8805; 15&#8201;mg/L <italic toggle="yes">vs</italic>. &lt; 15&#8201;mg/L or AUC/MIC ratio &#8805; 389&#8201;mg*h/L <italic toggle="yes">vs</italic>. &lt; 389&#8201;mg*h/L was performed to assess the correlation between vancomycin concentration and the primary and secondary outcomes.</p></sec><sec id="bcp16362-sec-0019"><label>3.4</label><title>All&#8208;cause mortality</title><p>Meta&#8208;analysis examining the effects of vancomycin trough level for all&#8208;cause mortality among 704 patients in five studies was conducted.<xref rid="bcp16362-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="bcp16362-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> There was no statistically significant difference in all&#8208;cause mortality between patients receiving treatment with vancomycin trough levels &#8805; 15&#8201;mg/L and those treated with vancomycin trough levels &lt; 15&#8201;mg/L (OR 1.18, 95% CI 0.42&#8211;3.34, <italic toggle="yes">I</italic>
<sup>2</sup>&#8201;=&#8201;73%), with no evidence of publication bias detected (Figure&#160;<xref rid="bcp16362-fig-0002" ref-type="fig">2A</xref>) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S2A</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">3</xref>). Removal of the studies by Nham et al.<xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> and Sasano and Hanada,<xref rid="bcp16362-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> in which 87.7% and 63.4% of patients had solid or haematologic malignancies, reduced heterogeneity and showed a trend toward lower mortality rate among individuals with high trough vancomycin regimen (OR 0.62, 95% CI 0.29&#8211;1.33, <italic toggle="yes">I</italic>
<sup>2</sup>&#8201;=&#8201;49%) (Figure&#160;<xref rid="bcp16362-fig-0002" ref-type="fig">2B</xref>) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S2B</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">3</xref>).</p><fig position="float" fig-type="FIGURE" id="bcp16362-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>(A) Odds ratio (OR) and 95% confidence intervals (CIs) for 30&#8208;day mortality comparing high trough (&#8805; 15&#8201;mg/L) with low trough vancomycin regimen (&lt; 15&#8201;mg/L). (B) Odds ratio (OR) and 95% confidence intervals (CIs) for 30&#8208;day mortality comparing high trough (&#8805; 15&#8201;mg/L) with low trough vancomycin regimen (&lt; 15&#8201;mg/L) after removing studies by Nham et al. and Sasano and Hanada. (C) Odds ratio (OR) and 95% confidence intervals (CIs) for 30&#8208;day mortality comparing high AUC/MIC (&#8805; 389&#8211;414.3&#160;mg*h/L) with low level vancomycin regimen (&lt; 389&#8211;414.3&#160;mg*h/L).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="BCP-91-1250-g004.jpg"/></fig><p>Pooled analyses of 897 patients with enterococcus infection in eight studies<xref rid="bcp16362-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="bcp16362-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="bcp16362-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="bcp16362-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="bcp16362-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="bcp16362-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="bcp16362-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> found that patients with high vancomycin AUC/MIC ratio (cut&#8208;off 389&#8211;414.3) had significantly lower all&#8208;cause mortality compared to those with low vancomycin AUC/MIC ratio (OR 0.38, 95% CI 0.20&#8211;0.72, <italic toggle="yes">I</italic>
<sup>2</sup>&#8201;=&#8201;48.8) (Figure&#160;<xref rid="bcp16362-fig-0002" ref-type="fig">2C</xref>) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S2C</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">3</xref>). Removal of two studies with target AUC/MIC breakpoint &#8805; 400 and 414.3&#160;mg*h/L from the analysis did not significantly alter the results (OR 0.44, 95% CI 0.26&#8211;0.75, <italic toggle="yes">I</italic>
<sup>2</sup>&#8201;=&#8201;0) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S2D</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">3</xref>), with no evidence of publication bias detected (Egger's test, <italic toggle="yes">P</italic>&#8201;=&#8201;.361).</p></sec><sec id="bcp16362-sec-0020"><label>3.5</label><title>Clinical failure</title><p>Pooled analysis of the included four studies among 695 patients<xref rid="bcp16362-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> demonstrated no significant difference regarding treatment failure rate between individuals receiving vancomycin high trough <italic toggle="yes">vs</italic>. low trough concentrations (OR 0.79, 95% CI 0.51&#8211;1.23, <italic toggle="yes">I</italic>
<sup>2</sup>&#8201;=&#8201;13.8%) (Figure&#160;<xref rid="bcp16362-fig-0003" ref-type="fig">3A</xref>) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S3A</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">3</xref>). Similarly, no significant difference in treatment failure rate among the high AUC/MIC group compared to the low AUC/MIC group was observed (OR 0.69, 95% CI 0.36&#8211;1.32, <italic toggle="yes">I</italic>
<sup>2</sup>&#8201;=&#8201;47.9%) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S3C</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">3</xref>). However, the analysis showed a significant lower clinical failure rate among the high AUC/MIC group (&#8805; 389&#8211;400&#8201;mg*h/L) compared to the low AUC/MIC group (&lt; 389&#8211;400&#8201;mg*h/L) (OR 0.59, 95% CI 0.37&#8211;0.94, <italic toggle="yes">I</italic>
<sup>2</sup>&#8201;=&#8201;4.2%) (Figure&#160;<xref rid="bcp16362-fig-0003" ref-type="fig">3B</xref>) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S3B</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">3</xref>) after removal of the study by Nham et al. with target AUC/MIC breakpoint &#8805; 504&#8201;mg*h/L.<xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="bcp16362-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>(A) Odds ratio (OR) and 95% confidence intervals (CIs) for clinical failure comparing high trough (&#8805; 15&#8201;mg/L) with low trough vancomycin regimen (&lt;15&#8201;mg/L). (B) Odds ratio (OR) and 95% confidence intervals (CIs) for clinical failure comparing high AUC/MIC (&#8805; 389&#8211;400&#8201;mg*h/L) with low level vancomycin regimen (&lt; 389&#8211;400&#8201;mg*h/L) after removing study by Nham et al.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="BCP-91-1250-g003.jpg"/></fig></sec><sec id="bcp16362-sec-0021"><label>3.6</label><title>Nephrotoxicity</title><p>Nephrotoxicity was substantially higher in patients who achieved a high trough vancomycin level compared to patients who achieved a low trough vancomycin level (OR 3.11, 95% CI 1.65&#8211;5.89, <italic toggle="yes">I</italic>
<sup>2</sup>&#8201;=&#8201;32.9%) (Figure&#160;<xref rid="bcp16362-fig-0004" ref-type="fig">4A</xref>) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S4A</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">3</xref>). Similarly, the incidence rates of nephrotoxicity caused by vancomycin were substantially greater at high AUC/MIC level compared to low AUC/MIC level (OR 2.95, 95% CI 1.60&#8211;5.44, <italic toggle="yes">I</italic>
<sup>2</sup>&#8201;=&#8201;0) (Figure&#160;<xref rid="bcp16362-fig-0004" ref-type="fig">4B</xref>) (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S4B</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">3</xref>). All included studies showed a significant higher nephrotoxicity rate among patients with high compared to low trough or AUC/MIC level except the study by Tochikura et al. in which the participants' mean estimated glomerular filtration rate (eGFR) was 83.5&#160;mL/min/1.73&#8201;m<sup>2</sup>.</p><fig position="float" fig-type="FIGURE" id="bcp16362-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>(A) Odds ratio (OR) and 95% confidence intervals (CIs) for nephrotoxicity comparing high trough (&#8805; 15&#8201;mg/L) with low trough vancomycin regimen (&lt; 15&#8201;mg/L). (B) Odds ratio (OR) and 95% confidence intervals (CIs) for nephrotoxicity comparing high AUC/MIC (&#8805; 389&#8201;mg*h/L) with low level vancomycin regimen (&lt; 389&#8201;mg*h/L).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="BCP-91-1250-g001.jpg"/></fig></sec><sec id="bcp16362-sec-0022"><label>3.7</label><title>Sensitivity analyses</title><p>Exclusion of the study by Nham et al., which recruited participants with solid or haematologic malignancies (87.7%) and the use of AUC/MIC target goal of &#8805; 504&#8201;mg*h/L and trough concentration &#8805; 13.94&#8201;mg/L,<xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> reduced heterogeneity. Subgroup analysis to assess the potential impact of studies with high risk of bias could not be executed due to the small number of studies included.</p></sec><sec id="bcp16362-sec-0023"><label>3.8</label><title>Risk of bias assessment</title><p>Among nine studies included,<xref rid="bcp16362-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="bcp16362-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="bcp16362-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="bcp16362-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="bcp16362-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="bcp16362-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> six studies were classified as low risk of bias<xref rid="bcp16362-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="bcp16362-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="bcp16362-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="bcp16362-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> while the remaining three studies were considered to have a moderate risk of bias<xref rid="bcp16362-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="bcp16362-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> according to the JBI Critical Appraisal Checklist for Cohort Studies (Table&#160;<xref rid="bcp16362-tbl-0002" ref-type="table">2</xref>) (Table&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S2.1</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">2</xref>).<xref rid="bcp16362-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Some items that were poorly reported included the strategies for dealing with confounding factors and the lack of follow&#8208;up information reported by these studies. Two studies also had unclear reporting regarding strategies to address the incomplete follow&#8208;up rates (Figure&#160;<xref rid="bcp16362-supitem-0001" ref-type="supplementary-material">S2.1</xref>, Supplementary Appendix <xref rid="bcp16362-supInfo-0001" ref-type="">2</xref>).<xref rid="bcp16362-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="bcp16362-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><table-wrap position="float" id="bcp16362-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Summary of rating using JBI critical appraisal checklist.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Item</th><th align="left" valign="bottom" rowspan="1" colspan="1">Nakakura et al. 2019</th><th align="left" valign="bottom" rowspan="1" colspan="1">Jumah et al. 2018</th><th align="left" valign="bottom" rowspan="1" colspan="1">Sohn et al. 2021</th><th align="left" valign="bottom" rowspan="1" colspan="1">Nham et al. 2022</th><th align="left" valign="bottom" rowspan="1" colspan="1">Katip &amp; Oberdorfer 2021</th><th align="left" valign="bottom" rowspan="1" colspan="1">Katip et al. 2022</th><th align="left" valign="bottom" rowspan="1" colspan="1">Komatsu et al. 2023</th><th align="left" valign="bottom" rowspan="1" colspan="1">Sasano &amp; Hanada 2023</th><th align="left" valign="bottom" rowspan="1" colspan="1">Tochikura et al. 2023</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Were the two groups similar and recruited from the same population?</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Were the exposures measured similarly to assign people to both exposed and unexposed group?</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Was the exposure measured in a valid and reliable way?</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Were confounding factors identified?</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Were strategies to deal with confounding factors stated?</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)?</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Were the outcomes measured in a valid and reliable way?</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Was the follow&#8208;up time reported and sufficient to be long enough for outcomes to occur?</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Was follow&#8208;up complete, and if not, were the reasons to loss to follow&#8208;up described and explored?</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Were strategies to address incomplete follow&#8208;up utilized?</td><td align="left" valign="top" rowspan="1" colspan="1">?</td><td align="left" valign="top" rowspan="1" colspan="1">?</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Was appropriate statistical analysis used?</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">?</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Score</td><td align="left" valign="top" rowspan="1" colspan="1">72.7</td><td align="left" valign="top" rowspan="1" colspan="1">81.8</td><td align="left" valign="top" rowspan="1" colspan="1">72.7</td><td align="left" valign="top" rowspan="1" colspan="1">72.7</td><td align="left" valign="top" rowspan="1" colspan="1">90.9</td><td align="left" valign="top" rowspan="1" colspan="1">81.8</td><td align="left" valign="top" rowspan="1" colspan="1">81.8</td><td align="left" valign="top" rowspan="1" colspan="1">81.8</td><td align="left" valign="top" rowspan="1" colspan="1">81.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rating</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Moderate</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Low</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Moderate</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Moderate</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Low</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Low</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Low</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Low</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Low</bold>
</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="bcp16362-sec-0024"><label>4</label><title>DISCUSSION</title><p>This systematic review and meta&#8208;analysis is the first study to our knowledge that synthesizes the available evidence regarding efficacy and safety of vancomycin therapeutic level for treatment of vancomycin&#8208;sensitive enterococcal infections both in terms of AUC/MIC ratio and target trough concentration. Results of this study affirm the possible correlation between vancomycin AUC/MIC, nephrotoxicity events and clinical outcomes for enterococcal infections.</p><p>In this study, we noted that keeping vancomycin area under the curve to minimum inhibitory concentration (AUC/MIC)&#8201;&#8805;&#8201;389&#8201;mg*h/L was significantly associated with reduced 30&#8208;day all&#8208;cause mortality, while maintaining a higher AUC/MIC &#8805; 389&#8211;400&#8201;mg*h/L was associated with significantly higher clinical success rates. However, it is critical to consider the elevated risk of nephrotoxicity associated with higher AUC/MIC ratio.</p><p>Vancomycin is well known for its potential to result in nephrotoxicity, but the extent of its contribution remains uncertain.<xref rid="bcp16362-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The reported incidence of nephrotoxicity varies and has been reported to be as low as 0% to 40%.<xref rid="bcp16362-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> This can be influenced by numerous factors, including concomitant nephrotoxic drugs, classification of acute kidney injury, pre&#8208;existing renal disorder, obesity, disease severity and vancomycin use.<xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="bcp16362-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The relationship between vancomycin exposure and acute kidney injury (AKI) has been investigated with moderate quality of evidence. A systematic review and meta&#8208;analysis suggested association between vancomycin use with AKI with the relative risk of 2.45 (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001).<xref rid="bcp16362-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> However, all included studies were at moderate to high risk of bias. Conversely, an RCT comparing standard treatment (anti&#8208;staphylococcal penicillin or vancomycin) in combination with low&#8208;dose gentamicin and daptomycin monotherapy for treating <italic toggle="yes">S. aureus</italic> bacteraemia and endocarditis demonstrated a similar rate in reducing creatinine clearance among those receiving vancomycin (10 out of 46; 22%) compared to penicillin (16 out of 63; 25%).<xref rid="bcp16362-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</p><p>Our findings affirm the clinical use of AUC/MIC, which is a good predictor of vancomycin clinical effectiveness and safety, consistent with earlier research.<xref rid="bcp16362-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="bcp16362-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Our pooled analysis results showed significant lower mortality rate among patients with enterococcal infections receiving vancomycin AUC/MIC&#8201;&#8805;&#8201;389&#8201;mg*h/L while maintaining serum vancomycin trough concentrations &#8805; 15&#8201;mg/L was not associated with this favourable clinical effect. Consistently, enterococcal infection patients with high vancomycin AUC/MIC had significantly higher clinical success rate compared to those with AUC/MIC at below 389&#8211;400&#8201;mg*h/L, whereas the incidence of clinical failure rate tended to be lower for high trough concentrations &#8805; 15&#8201;mg/L, but it was not significant in our meta&#8208;analysis. The findings from a prospective multicentre study investigating vancomycin efficacy with TDM in a Chinese population found that vancomycin trough concentration was not correlated with clinical outcomes but was associated with nephrotoxicity.<xref rid="bcp16362-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Consistently, another study in a paediatric population showed that trough concentrations were not reliable to estimate AUC/MIC and recommended not making vancomycin dosing adjustments based on trough concentrations only.<xref rid="bcp16362-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> This suggests that high trough concentrations are probably not superior to low trough concentrations and monitoring trough concentrations alone may not be sufficient.</p><p>In our analysis, both high AUC/MIC ratio and high trough concentrations were associated with higher rate of nephrotoxicity except in the study by Tochikura et al.<xref rid="bcp16362-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The discrepancy could be attributable to the high eGFR among study participants (83.5&#160;mL/min/1.73&#8201;m<sup>2</sup>) at baseline compared to the other studies. Significant association between vancomycin&#8208;induced nephrotoxicity and trough concentrations has been observed in many previous studies.<xref rid="bcp16362-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="bcp16362-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="bcp16362-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> It has been reported that a higher nephrotoxicity rate was associated with high trough regimen &#8805; 15&#8201;mg/L and the association was even more pronounced when the serum trough concentrations were &#8805;20&#8201;mg/L.<xref rid="bcp16362-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="bcp16362-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="bcp16362-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Due to this strong correlation, special precaution is needed for vancomycin TDM, and vancomycin trough concentrations should be targeted below 20&#8201;mg/L in any circumstances.</p><p>Our study suggests targeting an AUC/MIC target close to either the lower or upper end of the recommended range (389&#8211;400&#8201;mg*h/L) based on patient severity, as this is crucial for maintaining efficacy while minimizing nephrotoxicity risk. Several studies have demonstrated that nephrotoxicity risk progressively increases at higher AUC values, particularly beyond 600&#8201;mg*h/L, with a substantial rise at 1300&#8201;mg*h/L.<xref rid="bcp16362-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="bcp16362-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="bcp16362-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> In a TDM&#8208;guided study, the incidence of AKI was significantly lower (9.1%) when the AUC target was above 400&#8201;&#956;g*h/mL compared to a trough concentration&#8208;guided TDM within 15&#8211;20&#8201;&#956;g/mL (28.8%), highlighting the advantage of AUC&#8208;guided monitoring for minimizing nephrotoxicity.<xref rid="bcp16362-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> These findings underscore the importance of considering AUC/MIC as a continuous variable, as the risk of nephrotoxicity does not have a fixed threshold but rather escalates with increasing AUC values.</p><p>Individualized AUC/MIC targets based on patient&#8208;specific risk factors could further improve treatment safety and efficacy. For patients at higher risk of nephrotoxicity&#8212;such as those with pre&#8208;existing renal impairment, advanced age, prolonged treatment duration or concurrent use of nephrotoxic medications<xref rid="bcp16362-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>&#8212;a cautious approach to AUC/MIC targeting is crucial. Research exploring variables to refine optimal AUC/MIC thresholds across different patient populations is needed.</p><p>Most of our included studies suggested a trend towards reduced all&#8208;cause mortality among individuals treated with high vancomycin trough and AUC/MIC concentrations with the exception of two studies which showed significantly higher mortality rate at trough concentrations &#8805; 15&#8201;mg/L <italic toggle="yes">vs</italic>. &lt; 15&#8201;mg/L.<xref rid="bcp16362-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="bcp16362-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> The modest performance in reducing 30&#8208;day mortality might be explained by a high burden of patients with solid or haematologic malignancies and other comorbidities who might have insufficient immune response. Therefore, the mortality rate observed might have been attributable to other causes apart from enterococcal infections. The discrepancy of findings may be due to differences in the study populations, higher burden of <italic toggle="yes">E. faecium</italic> and small sample size.</p><p>Different antimicrobial susceptibility testing employed between studies might have had an impact on clinical outcomes. Most of the included studies used the Vitek&#8208;2 and a broth microdilution (BMD) method, which are widely used systems for testing antimicrobial susceptibility. An evaluation study comparing vancomycin MICs for <italic toggle="yes">enterococci</italic> results obtained by Vitek&#8208;2 and those obtained by the CLSI broth microdilution reported 100% essential and categorical agreements without any errors<xref rid="bcp16362-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> suggesting the test to be a reliable method. E&#8208;test was performed in one study by Jumah et al., which was also confirmed by automated BMD method with 100% categorial agreement.<xref rid="bcp16362-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Therefore, it is unlikely that this would have changed the conclusion of our study.</p><p>Several limitations can be noted in our study. First, all the included studies were retrospective cohort studies with limited sample size, which could have been potential for selection bias and confounding variables. Second, different methodological approaches might have had an impact on study outcomes. This includes variation of criteria used to define nephrotoxicity which might have resulted in variation of AKI incidences reported between studies. Also, different pharmacokinetic/pharmacodynamic analyses performed were probably responsible for the discrepancy of results and heterogeneity. It should be noted, however, that the heterogeneity in the pooled analysis was also secondary to the difference in study population, outcome definitions, enterococcal species identification, antimicrobial susceptibility testing and study setting. Third, all the studies included in the meta&#8208;analysis were conducted in East and Southeast Asia countries. This may limit generalizability as the results may not represent other regions and their populations. Therefore, the results in our analysis should be interpreted with caution. Prospective, well&#8208;designed randomized controlled trials and further meta&#8208;analysis are needed to elucidate the relationship of vancomycin concentrations and clinical outcomes for treating infections caused by <italic toggle="yes">enterococci</italic>.</p></sec><sec sec-type="conclusions" id="bcp16362-sec-0025"><label>5</label><title>CONCLUSION</title><p>According to the systematic review and meta&#8208;analysis, higher vancomycin AUC/MIC concentrations &#8805; 389&#8201;mg*h/L and &#8805; 389&#8211;400&#8201;mg*h/L are associated with reduced 30&#8208;day all&#8208;cause mortality and lowered clinical failure rates, respectively. Both vancomycin AUC/MIC &#8805; 389&#8201;mg*h/L and serum trough concentrations targeted &#8805; 15&#8201;mg/L are associated with higher nephrotoxicity rate. Given the paucity of evidence regarding vancomycin therapeutic level for treatment of enterococcal infections, prospective or well&#8208;design randomized controlled studies are warranted to settle the controversy.</p></sec><sec id="bcp16362-sec-0026"><title>AUTHOR CONTRIBUTIONS</title><p>All authors contributed to the study elaboration and design. W.K. and A.R. conceived and designed the study. A.R. and W.K. conducted searching, screening and data extraction, which were confirmed with S.W.H.L. and N.K. A.R. and S.W.H.L. performed quality assessment and created tables and figures which were confirmed by W.K. and N.K. A.R. conducted meta&#8208;analysis and interpreted the results with support from S.W.H.L. A.R. and W.K. drafted the manuscript, which was revised by A.R., N.K. and S.W.H.L. All authors read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="bcp16362-sec-0028"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare that they have no conflicts of interest. Also, the authors declare that the results presented in this paper have not been published previously in whole or part.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="bcp16362-supInfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="bcp16362-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S1.1</bold> Flow diagram of search strategy and study selection.</p><p>
<bold>Table S1.1.</bold> Details of 27 studies excluded after full&#8208;text review.</p><p>
<bold>Table S2.1.</bold> Summary of rating using JBI critical appraisal checklist.</p><p>
<bold>Table S2.1.</bold> Risk of bias summary using JBI critical appraisal checklist.</p><p>
<bold>Figure S2A.</bold> Odds ratio (OR) and 95% confidence intervals (CIs) for 30&#8208;day mortality comparing low trough (&lt; 15&#8201;mg/L) with high trough vancomycin regimen (&#8805; 15&#8201;mg/L).</p><p>
<bold>Figure S2B.</bold> Odds ratio (OR) and 95% confidence intervals (CIs) for 30&#8208;day mortality comparing low trough (&lt; 15&#8201;mg/L) with high trough vancomycin regimen (&#8805; 15&#8201;mg/L) after removing studies by Nham et al. and Sasano and Hanada.</p><p>
<bold>Figure S2C.</bold> Odds ratio (OR) and 95% confidence intervals (CIs) for 30&#8208;day mortality comparing high AUC/MIC (&#8805; 389&#8211;414.3&#160;mg*h/L) with low level vancomycin regimen (&lt; 389&#8211;414.3&#160;mg*h/L).</p><p>
<bold>Figure S2D.</bold> Odds ratio (OR) and 95% confidence intervals (CIs) for 30&#8208;day mortality comparing high AUC/MIC (&#8805; 389&#8201;mg*h/L) with low level vancomycin regimen (&lt; 389&#8201;mg*h/L) after removing studies with target AUC/MIC breakpoint &#8805; 400 and 414.3&#160;mg*h/L.</p><p>
<bold>Figure S3A.</bold> Odds ratio (OR) and 95% confidence intervals (CIs) for clinical failure comparing high trough (&#8805; 15&#8201;mg/L) with low trough vancomycin regimen (&lt; 15&#8201;mg/L).</p><p>
<bold>Figure S3B.</bold> Odds ratio (OR) and 95% confidence intervals (CIs) for clinical failure comparing high AUC/MIC (&#8805; 389&#8211;400&#8201;mg*h/L) with low level vancomycin regimen (&lt; 389&#8211;400&#8201;mg*h/L) after removing study by Nham et al.</p><p>
<bold>Figure S3C.</bold> Odds ratio (OR) and 95% confidence intervals (CIs) for clinical failure comparing high AUC/MIC (&#8805; 389&#8211;504&#8201;mg*h/L) with low level vancomycin regimen (&lt; 389&#8211;504&#8201;mg*h/L).</p><p>
<bold>Figure S4A.</bold> Odds ratio (OR) and 95% confidence intervals (CIs) for nephrotoxicity comparing high trough (&#8805; 15&#8201;mg/L) with low trough vancomycin regimen (&lt; 15&#8201;mg/L).</p><p>
<bold>Figure S4B.</bold> Odds ratio (OR) and 95% confidence intervals (CIs) for nephrotoxicity comparing high AUC/MIC (&#8805; 389&#8201;mg*h/L) with low level vancomycin regimen (&lt; 389&#8201;mg*h/L).</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BCP-91-1250-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="bcp16362-sec-0027"><title>ACKNOWLEDGEMENTS</title><p>This research was partially supported by Chiang Mai University. The authors would like to thank Narawan Prasanlak, Titirat Buthsingkhorn and Ratirat Inpa for their help with initial searching and screening.</p></ack><sec sec-type="data-availability" id="bcp16362-sec-0030"><title>DATA AVAILABILITY STATEMENT</title><p>The study data and materials are in the custody of the corresponding author and can be made available on reasonable request.</p></sec><ref-list id="bcp16362-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="bcp16362-bib-0001"><label>1</label><mixed-citation publication-type="book" id="bcp16362-cit-0002"><string-name name-style="western"><surname>Said</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tirthani</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lesho</surname><given-names>E</given-names></string-name>. <source>Enterococcus infections</source>. <publisher-name>StatPearls Publishing</publisher-name>; <year>2022</year>.<pub-id pub-id-type="pmid">33620836</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="bcp16362-cit-0003"><string-name name-style="western"><surname>Weiner&#8208;Lastinger</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Abner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>JR</given-names></string-name>, et al. <article-title>Antimicrobial&#8208;resistant pathogens associated with adult healthcare&#8208;associated infections: summary of data reported to the National Healthcare Safety Network, 2015&#8208;2017</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2020</year>;<volume>41</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1017/ice.2019.296</pub-id><pub-id pub-id-type="pmid">31767041</pub-id><pub-id pub-id-type="pmcid">PMC8276252</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="bcp16362-cit-0004"><string-name name-style="western"><surname>Hemapanpairoa</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Changpradub</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Santimaleeworagun</surname><given-names>W</given-names></string-name>. <article-title>Clinical impact of vancomycin treatment in ampicillin&#8208;susceptible enterococci bloodstream infections</article-title>. <source>Antibiotics (Basel, Switzerland)</source>. <year>2022</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1698</fpage>. doi:<pub-id pub-id-type="doi">10.3390/antibiotics11121698</pub-id><pub-id pub-id-type="pmid">36551355</pub-id><pub-id pub-id-type="pmcid">PMC9774542</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="bcp16362-cit-0005"><string-name name-style="western"><surname>Jumah</surname><given-names>MTB</given-names></string-name>, <string-name name-style="western"><surname>Vasoo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Menon</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>De</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Neely</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>CB</given-names></string-name>. <article-title>Pharmacokinetic/pharmacodynamic determinants of vancomycin efficacy in enterococcal bacteremia</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2018</year>;<volume>62</volume>(<issue>3</issue>). doi:<pub-id pub-id-type="doi">10.1128/AAC.01602-17</pub-id><pub-id pub-id-type="pmcid">PMC5826144</pub-id><pub-id pub-id-type="pmid">29263057</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="bcp16362-cit-0006"><string-name name-style="western"><surname>Rybak</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lomaestro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rotschafer</surname><given-names>JC</given-names></string-name>, et al. <article-title>Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health&#8208;System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists</article-title>. <source>Am J Health&#8208;Syst Pharm</source>. <year>2009</year>;<volume>66</volume>(<issue>1</issue>):<fpage>82</fpage>&#8208;<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.2146/ajhp080434</pub-id><pub-id pub-id-type="pmid">19106348</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="bcp16362-cit-0007"><string-name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Takesue</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ohmagari</surname><given-names>N</given-names></string-name>, et al. <article-title>Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring</article-title>. <source>J Infect Chemother</source>. <year>2013</year>;<volume>19</volume>(<issue>3</issue>):<fpage>365</fpage>&#8208;<lpage>380</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10156-013-0599-4</pub-id><pub-id pub-id-type="pmid">23673472</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="bcp16362-cit-0008"><string-name name-style="western"><surname>Rybak</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lodise</surname><given-names>TP</given-names></string-name>, et al. <article-title>Therapeutic monitoring of vancomycin for serious methicillin&#8208;resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health&#8208;System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists</article-title>. <source>Am J Health&#8208;Syst Pharm</source>. <year>2020</year>;<volume>77</volume>(<issue>11</issue>):<fpage>835</fpage>&#8208;<lpage>864</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ajhp/zxaa036</pub-id><pub-id pub-id-type="pmid">32191793</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="bcp16362-cit-0009"><string-name name-style="western"><surname>Hale</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Seabury</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Steele</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Darko</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>CD</given-names></string-name>. <article-title>Are vancomycin trough concentrations of 15 to 20 mg/L associated with increased attainment of an AUC/MIC &#8805; 400 in patients with presumed MRSA infection?</article-title><source>J Pharm Pract</source>. <year>2017</year>;<volume>30</volume>(<issue>3</issue>):<fpage>329</fpage>&#8208;<lpage>335</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0897190016642692</pub-id><pub-id pub-id-type="pmid">27074786</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="bcp16362-cit-0010"><string-name name-style="western"><surname>Neely</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Youn</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>B</given-names></string-name>, et al. <article-title>Are vancomycin trough concentrations adequate for optimal dosing?</article-title><source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>1</issue>):<fpage>309</fpage>&#8208;<lpage>316</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01653-13</pub-id><pub-id pub-id-type="pmid">24165176</pub-id><pub-id pub-id-type="pmcid">PMC3910745</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="bcp16362-cit-0011"><string-name name-style="western"><surname>Moise</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Forrest</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bhavnani</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Birmingham</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Schentag</surname><given-names>JJ</given-names></string-name>. <article-title>Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus</article-title>. <source>Am J Health&#8208;Syst Pharm</source>. <year>2000</year>;<volume>57</volume>(<issue>Suppl 2</issue>):<fpage>S4</fpage>&#8208;<lpage>S9</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ajhp/57.suppl_2.S4</pub-id><pub-id pub-id-type="pmid">11057360</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="bcp16362-cit-0012"><string-name name-style="western"><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liberati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>The</surname><given-names>PG</given-names></string-name>. <article-title>Preferred reporting items for systematic reviews and meta&#8208;analyses: The PRISMA statement</article-title>. <source>PLoS Med</source>. <year>2009</year>;<volume>6</volume>(<issue>7</issue>):<elocation-id>e1000097</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id><pub-id pub-id-type="pmid">19621072</pub-id><pub-id pub-id-type="pmcid">PMC2707599</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="bcp16362-cit-0013"><string-name name-style="western"><surname>Page</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></string-name>, et al. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source>. <year>2021</year>;<volume>372</volume>:<elocation-id>n71</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="bcp16362-cit-0014"><string-name name-style="western"><surname>Bellomo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ronco</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kellum</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Palevsky</surname><given-names>P</given-names></string-name>. <article-title>Acute renal failure&#8212;definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group</article-title>. <source>Crit Care</source>. <year>2004</year>;<volume>8</volume>(<issue>4</issue>):<fpage>R204</fpage>&#8208;<lpage>R212</lpage>. doi:<pub-id pub-id-type="doi">10.1186/cc2872</pub-id><pub-id pub-id-type="pmid">15312219</pub-id><pub-id pub-id-type="pmcid">PMC522841</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="bcp16362-cit-0015"><string-name name-style="western"><surname>Khwaja</surname><given-names>A</given-names></string-name>. <article-title>KDIGO clinical practice guidelines for acute kidney injury</article-title>. <source>Nephron Clin Pract</source>. <year>2012</year>;<volume>120</volume>(<issue>4</issue>):<fpage>c179</fpage>&#8208;<lpage>c184</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000339789</pub-id><pub-id pub-id-type="pmid">22890468</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="bcp16362-cit-0016"><string-name name-style="western"><surname>Moola</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Munn</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sears</surname><given-names>K</given-names></string-name>, et al. <article-title>Conducting systematic reviews of association (etiology): The Joanna Briggs Institute's approach</article-title>. <source>Int J Evid Based Healthc</source>. <year>2015</year>;<volume>13</volume>(<issue>3</issue>):<fpage>163</fpage>&#8208;<lpage>169</lpage>. doi:<pub-id pub-id-type="doi">10.1097/XEB.0000000000000064</pub-id><pub-id pub-id-type="pmid">26262566</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0016"><label>16</label><mixed-citation publication-type="book" id="bcp16362-cit-0017"><string-name name-style="western"><surname>Moola</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Munn</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tufanaru</surname><given-names>C</given-names></string-name>, et al. <part-title>Chapter 7: systematic reviews of etiology and risk</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Aromataris</surname><given-names>E</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Munn</surname><given-names>Z</given-names></string-name></person-group>, eds. <source>JBI manual for evidence synthesis</source>; <year>2020</year>. doi:<pub-id pub-id-type="doi">10.46658/JBIRM-17-06</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="bcp16362-cit-0018"><string-name name-style="western"><surname>Melo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dutra</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Rodrigues Filho</surname><given-names>R</given-names></string-name>, et al. <article-title>Association between psychotropic medications and presence of sleep bruxism: a systematic review</article-title>. <source>J Oral Rehabil</source>. <year>2018</year>;<volume>45</volume>(<issue>7</issue>):<fpage>545</fpage>&#8208;<lpage>554</lpage>. doi:<pub-id pub-id-type="doi">10.1111/joor.12633</pub-id><pub-id pub-id-type="pmid">29663484</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="bcp16362-cit-0019"><string-name name-style="western"><surname>Komatsu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Naito</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Akamada</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nihonyanagi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Otori</surname><given-names>K</given-names></string-name>. <article-title>Association between ratio of area under the concentration&#8211;time curve to minimum inhibitory concentration of vancomycin and clinical outcomes in <italic toggle="yes">Enterococcus faecium</italic> bacteremia</article-title>. <source>J Infect Chemother</source>. <year>2023</year>;<volume>29</volume>(<issue>12</issue>):<fpage>1181</fpage>&#8208;<lpage>1184</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jiac.2023.07.010</pub-id><pub-id pub-id-type="pmid">37524202</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="bcp16362-cit-0020"><string-name name-style="western"><surname>Nakakura</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sakakura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Imanishi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sako</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yamazaki</surname><given-names>K</given-names></string-name>. <article-title>Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin&#8208;susceptible Enterococcus faecium: a single&#8208;center retrospective study</article-title>. <source>J Pharm Health Care Sci</source>. <year>2019</year>;(<issue>1</issue>):<fpage>5</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40780-019-0138-2</pub-id><pub-id pub-id-type="pmid">31093330</pub-id><pub-id pub-id-type="pmcid">PMC6485087</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="bcp16362-cit-0021"><string-name name-style="western"><surname>Sasano</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hanada</surname><given-names>K</given-names></string-name>. <article-title>Assessing clinical outcomes of vancomycin treatment in adult patients with vancomycin&#8208;susceptible <italic toggle="yes">Enterococcus faecium</italic> bacteremia</article-title>. <source>Antibiotics (Basel)</source>. <year>2023</year>;<volume>12</volume>(<issue>11</issue>):<elocation-id>1577</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/antibiotics12111577</pub-id><pub-id pub-id-type="pmid">37998779</pub-id><pub-id pub-id-type="pmcid">PMC10668815</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="bcp16362-cit-0022"><string-name name-style="western"><surname>Tochikura</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Matsumoto</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Iwabuchi</surname><given-names>S</given-names></string-name>, et al. <article-title>Pharmacokinetic/pharmacodynamic analysis of vancomycin in patients with <italic toggle="yes">Enterococcus faecium</italic> bacteraemia: a retrospective cohort study</article-title>. <source>Eur J Hosp Pharm</source>. <year>2023</year>;<volume>31</volume>(<issue>5</issue>):<fpage>440</fpage>&#8208;<lpage>446</lpage>. doi:<pub-id pub-id-type="doi">10.1136/ejhpharm-2022-003672</pub-id><pub-id pub-id-type="pmid">36868850</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="bcp16362-cit-0023"><string-name name-style="western"><surname>Katip</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Oberdorfer</surname><given-names>P</given-names></string-name>. <article-title>A monocentric retrospective study of AUC/MIC ratio of vancomycin associated with clinical outcomes and nephrotoxicity in patients with enterococcal infections</article-title>. <source>Pharmaceutics</source>. <year>2021</year>;<volume>13</volume>(<issue>9</issue>):<elocation-id>1378</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/pharmaceutics13091378</pub-id><pub-id pub-id-type="pmid">34575453</pub-id><pub-id pub-id-type="pmcid">PMC8464995</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="bcp16362-cit-0024"><string-name name-style="western"><surname>Katip</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Okonogi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Oberdorfer</surname><given-names>P</given-names></string-name>. <article-title>The thirty&#8208;day mortality rate and nephrotoxicity associated with trough serum vancomycin concentrations during treatment of enterococcal infections: a propensity score matching analysis</article-title>. <source>Front Pharmacol</source>. <year>2022</year>;<volume>12</volume>:<fpage>12</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2021.773994</pub-id><pub-id pub-id-type="pmcid">PMC8831381</pub-id><pub-id pub-id-type="pmid">35153743</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="bcp16362-cit-0025"><string-name name-style="western"><surname>Nham</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Huh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sohn</surname><given-names>YM</given-names></string-name>, et al. <article-title>Pharmacokinetic/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia</article-title>. <source>BMC Infect Dis</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<elocation-id>686</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12879-022-07668-w</pub-id><pub-id pub-id-type="pmid">35948963</pub-id><pub-id pub-id-type="pmcid">PMC9364583</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="bcp16362-cit-0026"><string-name name-style="western"><surname>Sohn</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Rim</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>Y</given-names></string-name>, et al. <article-title>Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by enterococcus species</article-title>. <source>BMC Infect Dis</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<elocation-id>1099</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12879-021-06809-x</pub-id><pub-id pub-id-type="pmid">34702193</pub-id><pub-id pub-id-type="pmcid">PMC8547083</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="bcp16362-cit-0027"><string-name name-style="western"><surname>Katip</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Oberdorfer</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kasatpibal</surname><given-names>N</given-names></string-name>. <article-title>Effectiveness and nephrotoxicity of loading dose colistin&#8211;meropenem versus loading dose colistin&#8211;imipenem in the treatment of carbapenem&#8208;resistant Acinetobacter baumannii infection</article-title>. <source>Pharmaceutics</source>. <year>2022</year>;<volume>14</volume>(<issue>6</issue>):<elocation-id>1266</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/pharmaceutics14061266</pub-id><pub-id pub-id-type="pmid">35745838</pub-id><pub-id pub-id-type="pmcid">PMC9228626</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="bcp16362-cit-0028"><string-name name-style="western"><surname>Filippone</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Kraft</surname><given-names>WK</given-names></string-name>, <string-name name-style="western"><surname>Farber</surname><given-names>JL</given-names></string-name>. <article-title>The nephrotoxicity of vancomycin</article-title>. <source>Clin Pharmacol Ther</source>. <year>2017</year>;<volume>102</volume>(<issue>3</issue>):<fpage>459</fpage>&#8208;<lpage>469</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.726</pub-id><pub-id pub-id-type="pmid">28474732</pub-id><pub-id pub-id-type="pmcid">PMC5579760</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="bcp16362-cit-0029"><string-name name-style="western"><surname>Sinha Ray</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Haikal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hammoud</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>AS</given-names></string-name>. <article-title>Vancomycin and the risk of AKI: a systematic review and meta&#8208;analysis</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2016</year>;<volume>11</volume>(<issue>12</issue>):<fpage>2132</fpage>&#8208;<lpage>2140</lpage>. doi:<pub-id pub-id-type="doi">10.2215/CJN.05920616</pub-id><pub-id pub-id-type="pmid">27895134</pub-id><pub-id pub-id-type="pmcid">PMC5142072</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="bcp16362-cit-0030"><string-name name-style="western"><surname>Cosgrove</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Campion</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vigliani</surname><given-names>GA</given-names></string-name>, et al. <article-title>Initial low&#8208;dose gentamicin for <italic toggle="yes">Staphylococcus aureus</italic> bacteremia and endocarditis is nephrotoxic</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>;<volume>48</volume>(<issue>6</issue>):<fpage>713</fpage>&#8208;<lpage>721</lpage>.<pub-id pub-id-type="pmid">19207079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/597031</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="bcp16362-cit-0031"><string-name name-style="western"><surname>Finch</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Zasowski</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>KP</given-names></string-name>, et al. <article-title>A quasi&#8208;experiment to study the impact of vancomycin area under the concentration&#8211;time curve&#8208;guided dosing on vancomycin&#8208;associated nephrotoxicity</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>;<volume>61</volume>(<issue>12</issue>). doi:<pub-id pub-id-type="doi">10.1128/AAC.01293-17</pub-id><pub-id pub-id-type="pmcid">PMC5700348</pub-id><pub-id pub-id-type="pmid">28923869</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="bcp16362-cit-0032"><string-name name-style="western"><surname>Liang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, et al. <article-title>A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring</article-title>. <source>Clin Infect Dis</source>. <year>2018</year>;<volume>67</volume>(<issue>suppl_2</issue>):<fpage>S249</fpage>&#8208;<lpage>S255</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciy680</pub-id><pub-id pub-id-type="pmid">30423040</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="bcp16362-cit-0033"><string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, et al. <article-title>Vancomycin population pharmacokinetics analysis in Chinese paediatric patients with varying degrees of renal function and ages: development of new practical dosing recommendations</article-title>. <source>J Antimicrob Chemother</source>. <year>2023</year>;<volume>78</volume>(<issue>8</issue>):<fpage>2037</fpage>&#8208;<lpage>2051</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkad202</pub-id><pub-id pub-id-type="pmid">37379498</pub-id><pub-id pub-id-type="pmcid">PMC10393882</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="bcp16362-cit-0034"><string-name name-style="western"><surname>Bellos</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Daskalakis</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pergialiotis</surname><given-names>V</given-names></string-name>. <article-title>Relationship of vancomycin trough levels with acute kidney injury risk: an exposure&#8208;toxicity meta&#8208;analysis</article-title>. <source>J Antimicrob Chemother</source>. <year>2020</year>;<volume>75</volume>(<issue>10</issue>):<fpage>2725</fpage>&#8208;<lpage>2734</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkaa184</pub-id><pub-id pub-id-type="pmid">32417905</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="bcp16362-cit-0035"><string-name name-style="western"><surname>Horey</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mergenhagen</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Mattappallil</surname><given-names>A</given-names></string-name>. <article-title>The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis</article-title>. <source>Ann Pharmacother</source>. <year>2012</year>;<volume>46</volume>(<issue>11</issue>):<fpage>1477</fpage>&#8208;<lpage>1483</lpage>. doi:<pub-id pub-id-type="doi">10.1345/aph.1R158</pub-id><pub-id pub-id-type="pmid">23073306</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="bcp16362-cit-0036"><string-name name-style="western"><surname>Tongsai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Koomanachai</surname><given-names>P</given-names></string-name>. <article-title>The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin&#8208;resistant Staphylococcus aureus: a meta&#8208;analysis</article-title>. <source>BMC Res Notes</source>. <year>2016</year>;<volume>9</volume>(<issue>1</issue>):<elocation-id>455</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s13104-016-2252-7</pub-id><pub-id pub-id-type="pmid">27686168</pub-id><pub-id pub-id-type="pmcid">PMC5041442</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="bcp16362-cit-0037"><string-name name-style="western"><surname>Suzuki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kawasaki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>Y</given-names></string-name>, et al. <article-title>Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic&#8208;pharmacodynamic analysis in patients with methicillin&#8208;resistant Staphylococcus aureus pneumonia</article-title>. <source>Chemotherapy</source>. <year>2012</year>;<volume>58</volume>(<issue>4</issue>):<fpage>308</fpage>&#8208;<lpage>312</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000343162</pub-id><pub-id pub-id-type="pmid">23147106</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="bcp16362-cit-0038"><string-name name-style="western"><surname>Lodise</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lomaestro</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></string-name>. <article-title>Relationship between initial vancomycin concentration&#8211;time profile and nephrotoxicity among hospitalized patients</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>;<volume>49</volume>(<issue>4</issue>):<fpage>507</fpage>&#8208;<lpage>514</lpage>. doi:<pub-id pub-id-type="doi">10.1086/600884</pub-id><pub-id pub-id-type="pmid">19586413</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="bcp16362-cit-0039"><string-name name-style="western"><surname>Chavada</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sandaradura</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Maley</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Van Hal</surname><given-names>SJ</given-names></string-name>. <article-title>Establishment of an AUC<sub>0&#8208;24</sub> threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin&#8208;resistant Staphylococcus aureus bacteremia</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>;<volume>61</volume>(<issue>5</issue>):<elocation-id>e02535&#8208;16</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/AAC.02535-16</pub-id><pub-id pub-id-type="pmid">28242672</pub-id><pub-id pub-id-type="pmcid">PMC5404579</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="bcp16362-cit-0040"><string-name name-style="western"><surname>Oda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jono</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nosaka</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Saito</surname><given-names>H</given-names></string-name>. <article-title>Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration&#8211;time curve against a trough 15&#8208;20 &#956;g/mL concentration</article-title>. <source>Int J Antimicrob Agents</source>. <year>2020</year>;<volume>56</volume>(<issue>4</issue>):<elocation-id>106109</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106109</pub-id><pub-id pub-id-type="pmid">32721597</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="bcp16362-cit-0041"><string-name name-style="western"><surname>Kan</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>VC</given-names></string-name>, <string-name name-style="western"><surname>Shiao</surname><given-names>CC</given-names></string-name>. <article-title>Vancomycin&#8208;associated acute kidney injury: a narrative review from pathophysiology to clinical application</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>(<issue>4</issue>):<fpage>2052</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms23042052</pub-id><pub-id pub-id-type="pmid">35216167</pub-id><pub-id pub-id-type="pmcid">PMC8877514</pub-id></mixed-citation></ref><ref id="bcp16362-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="bcp16362-cit-0042"><string-name name-style="western"><surname>Bobenchik</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Hindler</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Giltner</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Saeki</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Humphries</surname><given-names>RM</given-names></string-name>. <article-title>Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp</article-title>. <source>J Clin Microbiol</source>. <year>2014</year>;<volume>52</volume>(<issue>2</issue>):<fpage>392</fpage>&#8208;<lpage>397</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.02432-13</pub-id><pub-id pub-id-type="pmid">24478467</pub-id><pub-id pub-id-type="pmcid">PMC3911353</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>